Cargando…

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study

CONTEXT: The effect of pegvisomant on IGF1 levels in patients with acromegaly is well documented, but little is known of its long-term impact on comorbidity. AIM: The aim of this retrospective study was to evaluate the effects of long-term pegvisomant therapy on cardiorespiratory and metabolic comor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuhn, Emmanuelle, Maione, Luigi, Bouchachi, Amir, Rozière, Myriam, Salenave, Sylvie, Brailly-Tabard, Sylvie, Young, Jacques, Kamenicky, Peter, Assayag, Patrick, Chanson, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592912/ https://www.ncbi.nlm.nih.gov/pubmed/26429918 http://dx.doi.org/10.1530/EJE-15-0500

Ejemplares similares

Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas
por: Paepegaey, Anne-Cécile, et al.
Publicado: (2017)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Acromegaly
por: Chanson, Philippe, et al.
Publicado: (2008)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

THU059 Increased Intracellular And Extracellular Myocardial Masses On Cardiac Magnetic Resonance Imaging In Patents With Acromegaly
por: Wolf, Peter, et al.
Publicado: (2023)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

OR11-05 Clinical Characteristics and Reproductive Hormone Levels in 201 Men With Congenital and 479 Men With Acquired Hypogonadotropic Hypogonadism: A Single-Center Comparative Study
por: MAIONE, Luigi, et al.
Publicado: (2020)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea
por: Millar, Robert P., et al.
Publicado: (2017)

Differentiating pathologic parathyroid glands from thyroid nodules on neck ultrasound: the PARATH-US cross-sectional study
por: Yazgi, Dolly, et al.
Publicado: (2023)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging Study
por: Kamenický, Peter, et al.
Publicado: (2014)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2021)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males
por: Mosbah, Helena, et al.
Publicado: (2019)

A Somewhat Bizarre Case of Graves Disease Due to Vitamin Treatment
por: Al-Salameh, Abdallah, et al.
Publicado: (2017)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays
por: Chanson, Philippe, et al.
Publicado: (2016)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
por: Moore, David J, et al.
Publicado: (2009)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Serum inhibin B concentration as a predictor of age at first menstruation in girls with idiopathic central precocious puberty
por: Tencer, Jérémie, et al.
Publicado: (2018)

Puberty and Inhibin B in 35 Adolescents With Pituitary Stalk Interruption Syndrome
por: Corvest, Victoria, et al.
Publicado: (2020)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations
por: Francou, Bruno, et al.
Publicado: (2011)

OR17-05 Lysine Demethylase KDM1A And Ectopic Expression Of GIP-Receptor In Somatotropinomas Of Patients With Paradoxical Response To Oral Glucose
por: Chasseloup, Fanny, et al.
Publicado: (2023)

Diagnosis of acromegaly: black, white… and sometimes gray!
por: Chanson, Philippe
Publicado: (2016)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_covgh74gd86gc34c4af9nh7qp0